Linked Life Data

20002306

Source:http://linkedlifedata.com/resource/pubmed/id/20002306

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2010-11-2
pubmed:abstractText
The prevalence of hepatitis C virus (HCV) infection varies across the world, with the highest number of infections reported in Egypt. Expression of the MxA gene has been found to be a reliable and sensitive marker for the induction of endogenous type I interferons (IFNs) during viral infections. This study examined the correlation of gene expression of MxA with the response to treatment with pegylated-IFN-alfa2b and ribavirin. Fifty patients with type 4 HCV and 20 healthy volunteers as controls were enrolled in a prospective study designed with strict inclusion criteria to nullify the effect of confounding variables and further minimize selection bias. Quantification of HCV-RNA and MxA gene by real-time PCR was performed for every patient, and quantification of MxA gene was performed for controls. There was a statistically significant difference between patients and control group as regards the quantity of MxA gene expression (P < 0.05) (Mann-Whitney test) (P = 0.004). There was a statistically significant difference between responders and nonresponders (P < 0.05): responders showed a higher percentage of cases with initial MxA <2(6) (P < 0.05). We conclude that MxA protein expression is a sensitive biological marker for ongoing virus replication and presence of type 1 IFN. These results highlight the importance of the detection of MxA expression at the start of therapy as a factor for assessing the likelihood of HCV genotype 4 patients to achieving a sustained virological response to treatment with IFN-?2 in combination with ribavirin.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1365-2893
pubmed:author
pubmed:copyrightInfo
© 2009 Blackwell Publishing Ltd.
pubmed:issnType
Electronic
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
794-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:20002306-Adolescent, pubmed-meshheading:20002306-Adult, pubmed-meshheading:20002306-Antiviral Agents, pubmed-meshheading:20002306-Biological Markers, pubmed-meshheading:20002306-Drug Monitoring, pubmed-meshheading:20002306-Egypt, pubmed-meshheading:20002306-Female, pubmed-meshheading:20002306-GTP-Binding Proteins, pubmed-meshheading:20002306-Gene Expression, pubmed-meshheading:20002306-Gene Expression Profiling, pubmed-meshheading:20002306-Genotype, pubmed-meshheading:20002306-Hepacivirus, pubmed-meshheading:20002306-Hepatitis C, pubmed-meshheading:20002306-Humans, pubmed-meshheading:20002306-Interferon-alpha, pubmed-meshheading:20002306-Male, pubmed-meshheading:20002306-Middle Aged, pubmed-meshheading:20002306-Polyethylene Glycols, pubmed-meshheading:20002306-RNA, Messenger, pubmed-meshheading:20002306-RNA, Viral, pubmed-meshheading:20002306-Recombinant Proteins, pubmed-meshheading:20002306-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:20002306-Viral Load, pubmed-meshheading:20002306-Young Adult
pubmed:year
2010
pubmed:articleTitle
MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients.
pubmed:affiliation
epartment of Medical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt.
pubmed:publicationType
Journal Article